Examining the trend of mortality of genitourinary system cancers in Babol, North Iran (2013-2021).
Genitourinary cancers
Iran
Mortality
Trends
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
07
03
2024
accepted:
24
06
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
Cancers of the genitourinary system, particularly prostate, bladder, and kidney cancer, exhibit a high prevalence. Consequently, predicting the morbidity and mortality of genitourinary cancers holds great significance for future planning and implementation. This study aimed to examine the crude and age-standardized rates of mortality and the trend of genitourinary cancers over nine years in northern Iran. This cross-sectional study used data on the number of deaths attributed to genitourinary cancers recorded in Babol City between 2013 and 2021 through the cause of death registration and classification system. Population estimates were derived from the latest census reports. Subsequently, crude and age-standardized rates, as well as trends for genitourinary cancers, were calculated. A total of 307 deaths occurred, with an average age of 75.6 ± 14.3 years due to genitourinary cancers. The crude and age-standardized rates of genitourinary cancers increased from 2.7 and 1.9 per hundred thousand people in 2013 to 7.7 and 5.9 per hundred thousand people in 2021, respectively. Over the study period, death rates significantly rose for men (P < 0.001) and remained constant for women (P = 0.444). Examination of genitourinary cancers revealed an upward trend for bladder (P = 0.012) and prostate (P = 0.012) cancers, while a stable trend was observed for kidney (P = 0.070) and testicular (P = 0.139) cancers. The age-standardized rate and trend of genitourinary cancers are rising. Consequently, this study emphasizes the importance of prevention through screening programs, raising awareness, and utilizing appropriate diagnostic methods.
Sections du résumé
BACKGROUND
BACKGROUND
Cancers of the genitourinary system, particularly prostate, bladder, and kidney cancer, exhibit a high prevalence. Consequently, predicting the morbidity and mortality of genitourinary cancers holds great significance for future planning and implementation. This study aimed to examine the crude and age-standardized rates of mortality and the trend of genitourinary cancers over nine years in northern Iran.
METHODS
METHODS
This cross-sectional study used data on the number of deaths attributed to genitourinary cancers recorded in Babol City between 2013 and 2021 through the cause of death registration and classification system. Population estimates were derived from the latest census reports. Subsequently, crude and age-standardized rates, as well as trends for genitourinary cancers, were calculated.
RESULTS
RESULTS
A total of 307 deaths occurred, with an average age of 75.6 ± 14.3 years due to genitourinary cancers. The crude and age-standardized rates of genitourinary cancers increased from 2.7 and 1.9 per hundred thousand people in 2013 to 7.7 and 5.9 per hundred thousand people in 2021, respectively. Over the study period, death rates significantly rose for men (P < 0.001) and remained constant for women (P = 0.444). Examination of genitourinary cancers revealed an upward trend for bladder (P = 0.012) and prostate (P = 0.012) cancers, while a stable trend was observed for kidney (P = 0.070) and testicular (P = 0.139) cancers.
CONCLUSIONS
CONCLUSIONS
The age-standardized rate and trend of genitourinary cancers are rising. Consequently, this study emphasizes the importance of prevention through screening programs, raising awareness, and utilizing appropriate diagnostic methods.
Identifiants
pubmed: 39080636
doi: 10.1186/s12894-024-01523-7
pii: 10.1186/s12894-024-01523-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161Informations de copyright
© 2024. The Author(s).
Références
Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.
pubmed: 34272515
doi: 10.1038/s41568-021-00378-6
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Shafiee G, Mousavian AH, Sheidaei A, Ebrahimi M, Khatami F, Gohari K, et al. The 15-year national trends of genital cancer incidence among Iranian men and women; 2005–2020. BMC Public Health. 2023;23(1):495.
pubmed: 36922819
pmcid: 10015665
doi: 10.1186/s12889-023-15417-0
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
pubmed: 29313949
doi: 10.3322/caac.21442
Merriel SW, Seggie A, Ahmed H. Diagnosis of prostate cancer in primary care: navigating updated clinical guidance. Br J Gen Pract. 2023;73(727):54–5.
pubmed: 36702599
pmcid: 9888566
doi: 10.3399/bjgp23X731769
Yaxley JP. Urinary tract cancers: an overview for general practice. J Family Med Prim Care. 2016;5(3):533–8.
pubmed: 28217578
pmcid: 5290755
doi: 10.4103/2249-4863.197258
Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, et al. European Association of Urology Guidelines on Upper urinary tract Urothelial Carcinoma: 2023 update. Eur Urol. 2023;84(1):49–64.
pubmed: 36967359
doi: 10.1016/j.eururo.2023.03.013
Tian YQ, Yang JC, Hu JJ, Ding R, Ye DW, Shang JW. Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: systematic analysis for the global burden of Disease Study 2019. Front Public Health. 2023;11:1119374.
pubmed: 36908450
pmcid: 9992434
doi: 10.3389/fpubh.2023.1119374
O’Hare B, Makuta I, Chiwaula L, Bar-Zeev N. Income and child mortality in developing countries: a systematic review and meta-analysis. J R Soc Med. 2013;106(10):408–14.
pubmed: 23824332
pmcid: 3791093
doi: 10.1177/0141076813489680
Khosravi A, Taylor R, Naghavi M, Lopez AD. Mortality in the Islamic Republic of Iran, 1964–2004. Bull World Health Organ. 2007;85(8):607–14.
pubmed: 17768519
pmcid: 2636375
doi: 10.2471/BLT.06.038802
World Health Organization. International classification of diseases for oncology (ICD-O). 3rd ed, 1st revision. Geneva: World Health Organization; 2013;2013.
Khajuria A, Kushte SS. Genitourinary cancer: a perspective review. Santosh Univ J Health Sci. 2022;8(2):111–5.
doi: 10.4103/sujhs.sujhs_42_22
International Agency for Research on Cancer. Cancer today. Data visualization tools for exploring the global cancer burden in 2020 [Internet]. [cited January 6, 2023]. https://gco.iarc.fr/today/home .
Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol. 2008;10(2):111–9.
pubmed: 18660852
pmcid: 2483315
Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iran J Public Health. 2018;47(3):309–16.
pubmed: 29845017
pmcid: 5971166
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
pubmed: 25220842
doi: 10.1002/ijc.29210
Özdemir BC, Dotto GP. Racial differences in Cancer susceptibility and survival: more than the Color of the skin? Trends Cancer. 2017;3(3):181–97.
pubmed: 28718431
pmcid: 5518637
doi: 10.1016/j.trecan.2017.02.002
Katzke VA, Kaaks R, Kühn T. Lifestyle and cancer risk. Cancer J. 2015;21(2):104–10.
pubmed: 25815850
doi: 10.1097/PPO.0000000000000101
Djalalinia S, Modirian M, Sheidaei A, Yoosefi M, Zokaiee H, Damirchilu B, et al. Protocol Design for large-scale cross-sectional studies of Surveillance of Risk factors of non-communicable diseases in Iran: STEPs 2016. Arch Iran Med. 2017;20(9):608–16.
pubmed: 29048923
Beal T, Morris SS, Tumilowicz A. Global Patterns of Adolescent Fruit, Vegetable, Carbonated Soft drink, and fast-food consumption: a Meta-analysis of Global School-based student health surveys. Food Nutr Bull. 2019;40(4):444–59.
pubmed: 31617415
doi: 10.1177/0379572119848287
Yang DX, Soulos PR, Davis B, Gross CP, Yu JB. Impact of widespread cervical Cancer screening: number of cancers prevented and changes in race-specific incidence. Am J Clin Oncol. 2018;41(3):289–94.
pubmed: 26808257
pmcid: 4958036
doi: 10.1097/COC.0000000000000264
Miller DC, Ruterbusch J, Colt JS, Davis FG, Linehan WM, Chow W-H, et al. Contemporary clinical epidemiology of renal cell carcinoma: insight from a Population Based Case-Control Study. J Urol. 2010;184(6):2254–8.
pubmed: 20952033
pmcid: 3059076
doi: 10.1016/j.juro.2010.08.018
Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–57.
pubmed: 20448658
pmcid: 3012455
doi: 10.1038/nrurol.2010.46
Patel AR, Prasad SM, Shih YC, Eggener SE. The association of the human development index with global kidney cancer incidence and mortality. J Urol. 2012;187(6):1978–83.
pubmed: 22498216
doi: 10.1016/j.juro.2012.01.121
Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff’s Clinical Oncology E-Book: Elsevier Health Sciences; 2013.
Bhanvadia SK. Bladder Cancer Survivorship. Curr Urol Rep. 2018;19(12):111.
pubmed: 30414013
doi: 10.1007/s11934-018-0860-6
Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am. 2015;29(2):237–52. viii.
pubmed: 25836932
doi: 10.1016/j.hoc.2014.10.011
Shanmugalingam T, Soultati A, Chowdhury S, Rudman S, Van Hemelrijck M. Global incidence and outcome of testicular cancer. Clin Epidemiol. 2013;5:417–27.
pubmed: 24204171
pmcid: 3804606
Le Cornet C, Lortet-Tieulent J, Forman D, Béranger R, Flechon A, Fervers B, et al. Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data. Eur J Cancer. 2014;50(4):831–9.
pubmed: 24369860
doi: 10.1016/j.ejca.2013.11.035
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
pubmed: 30207593
doi: 10.3322/caac.21492
McGlynn KA, Trabert B. Adolescent and adult risk factors for testicular cancer. Nat Rev Urol. 2012;9(6):339–49.
pubmed: 22508459
pmcid: 4031676
doi: 10.1038/nrurol.2012.61
Ferguson L, Agoulnik AI. Testicular cancer and cryptorchidism. Front Endocrinol (Lausanne). 2013;4:32.
pubmed: 23519268
doi: 10.3389/fendo.2013.00032